ENTITY
Innovent Biologics Inc

Innovent Biologics Inc (1801 HK)

357
Analysis
Health CareChina
Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.
more
Refresh
bearishSoftbank Group
05 Nov 2018 06:03

Last Week in GER Research: Softbank, Babytree, Tencent Music, MYOB, Yancoal, Spotify Warning & More!

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team.  Last week, Arun initiated IPO coverage...

Logo
305 Views
Share
bullishSoftbank Group
03 Nov 2018 13:40

ECM Weekly (3 November 2018) - TFFIF, Innovent, Softbank, Zhaogang - Open the IPO Floodgate!

Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...

Share
01 Nov 2018 14:21

Innovent Biologics (信达生物) Post IPO: Hit Our TP, What's Next?

Innovent Biologics was priced at the high end and it started trading yesterday (November 1st). It traded up by 18.5% on the first day and 8% on the...

Logo
532 Views
Share
31 Oct 2018 16:39

Innovent Biologics IPO First-Day: Take Money off the Table

Despite a recent spell of lacklustre early-stage biotech flotations that have slumped post-IPO, Innovent Biologics Inc (1801 HK)'s shares popped...

Logo
515 Views
Share
bearishTencent
20 Oct 2018 19:18

Last Week in GER Research: Tencent Backed IPOs, Niu, Innovent Biologics, Babytree and Fujifilm

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team. This week we highlight a very differentiated...

Logo
652 Views
Share
x